{
    "data": [
        {
            "title": "Major Drilling Adds Shannon McCrae To Board As Valuation Draws Attention",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Major Drilling Group International appointed experienced mining executive Shannon McCrae to its Board of Directors.</li> <li>McCrae brings a background in mineral exploration and mining operations from leadership roles at major global mining companies and industry boards.</li> </ul> <p>For investors tracking TSX:MDI, this Board change comes at a time when the share price sits at CA$18.22, with the stock up 8.3% over the past week and 13.1% over the past month. The move also follows longer term share price increases, including a 36.3% gain year to date and 121.7% over the past year.</p> <p>McCrae‚Äôs appointment indicates a focus on exploration depth and operational execution as the company prepares for potential shifts in drilling demand heading into 2026. For shareholders, an important consideration will be how her experience influences capital allocation, project mix, and the company‚Äôs positioning across mining cycles.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/ca/materials/tsx-mdi/major-drilling-group-international-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Major Drilling Group International</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/TSX/MDI\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Major Drilling Group International.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/ca/materials/tsx-mdi/major-drilling-group-international-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSX:MDI 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/d580fb22-fcc4-42c3-bb30-c74c962aa0ec/chart/quote-price?date=2026-02-28\" width=\"746\"/></a><figcaption>TSX:MDI 1-Year Stock Price Chart</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_management\" href=\"https://www.simplywall.st/stocks/ca/materials/tsx-mdi/major-drilling-group-international-shares/management\" rel=\"noopener noreferrer\" target=\"_blank\">Does the team leading Major Drilling Group International have what it takes? See our full breakdown of the management team's track record and compensation.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚öñÔ∏è Price vs Analyst Target</strong>: At CA$18.22, the share price is about 11.6% below the CA$20.62 analyst target, which is close to analysts' central range.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Shares are flagged as trading 17.3% below estimated fair value, which may be of interest to value focused investors.</li> <li><strong>‚úÖ Recent Momentum</strong>: A 13.1% gain over the past 30 days indicates the market has been responding positively ahead of this Board change.</li> </ul> <p>To assess whether it may be an appropriate time to buy, sell or hold Major Drilling Group International, you can review Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/ca/materials/tsx-mdi/major-drilling-group-international-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of Major Drilling Group International's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä McCrae joining the Board is closely connected to Major Drilling Group International‚Äôs core business in mineral exploration, so you may want to watch how Board guidance shapes drilling focus and capital deployment.</li> <li>üìä With the stock near CA$18.22 versus a CA$20.62 analyst target and Simply Wall St flagging a 17.3% discount to fair value, it may be useful to monitor any updates to earnings expectations and contract activity following her appointment.</li> <li>‚ö†Ô∏è Net profit margin of 1.7% compared with 4.9% last year highlights execution and profitability as key areas to watch as the refreshed Board influences strategy.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture, including more risks and potential rewards, you can review the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/ca/materials/tsx-mdi/major-drilling-group-international-shares\" rel=\"noopener noreferrer\" target=\"_blank\">complete Major Drilling Group International analysis</a>. You can also visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/TSX/MDI\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Major Drilling Group International</a> to see how other investors believe this latest news may affect the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 04:00:55",
            "link": "https://simplywall.st/stocks/ca/materials/tsx-mdi/major-drilling-group-international-shares/news/major-drilling-adds-shannon-mccrae-to-board-as-valuation-dra",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Xiaomi Supreme Court Royalty Case And What It Means For Valuation",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Xiaomi has taken its tariff and royalty dispute to India's Supreme Court, challenging a tribunal ruling on how certain payments tied to imports should be taxed.</li> <li>The case centers on whether royalty payments linked to technology and brand use should be added to the customs value of imported components.</li> <li>The outcome could shape future tax treatment for contract manufacturing arrangements used by Xiaomi and other multinational producers in India.</li> </ul> <p> Xiaomi, traded as SEHK:1810, is contesting this ruling at a time when its stock has seen mixed recent performance. The share price stands at HK$34.9, with a 3 year return that is very large and a 5 year return of 42.7%, while the 1 year return shows a 32.7% decline. Short term moves have been more modest, including a 1.3% decline over the past week and a 3.9% decline over the past month.\n</p> <p> For investors watching Xiaomi and other hardware manufacturers that rely on Indian contract production, this Supreme Court case is worth monitoring. Any change in how import linked royalty payments are taxed could influence cost structures, supply chain decisions, and how companies think about future compliance in India.\n</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/hk/tech/hkg-1810/xiaomi-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Xiaomi</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/SEHK/1810\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Xiaomi.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/hk/tech/hkg-1810/xiaomi-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"SEHK:1810 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9bf995c8-7b84-4921-86e8-71da4338df20/chart/quote-price?date=2026-02-28\" width=\"746\"/></a><figcaption>SEHK:1810 1-Year Stock Price Chart</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_financial_health\" href=\"https://www.simplywall.st/stocks/hk/tech/hkg-1810/xiaomi-shares/health\" rel=\"noopener noreferrer\" target=\"_blank\">Is Xiaomi's balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At HK$34.9 versus an average analyst target of about HK$55.9, the price sits roughly 38% below consensus.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Xiaomi is described as trading about 34.7% below estimated fair value, which flags it as undervalued in that model.</li> <li><strong>‚ùå Recent Momentum</strong>: The 30 day return of about 3.9% decline signals weak short term sentiment while this case is in focus.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Xiaomi. Head to the Simply Wall St\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/hk/tech/hkg-1810/xiaomi-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of Xiaomi's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The Supreme Court challenge could affect Xiaomi's cost base in India, which matters given its role as a contract manufacturing hub.</li> <li>üìä Keep an eye on the HK$34.9 price versus both the analyst target range and the P/E of 18.0 relative to the Tech industry average of 18.0.</li> <li>‚ö†Ô∏è Large one off items affecting earnings have been highlighted as a risk, so factor that in when assessing profitability around any tax related outcomes.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/hk/tech/hkg-1810/xiaomi-shares\" rel=\"noopener noreferrer\" target=\"_blank\">complete Xiaomi analysis</a>. Alternatively, you can check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/SEHK/1810\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Xiaomi</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 04:00:55",
            "link": "https://simplywall.st/stocks/hk/tech/hkg-1810/xiaomi-shares/news/xiaomi-supreme-court-royalty-case-and-what-it-means-for-valu",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Mohawk Industries Weighs Latin America Growth Against Legal And Cost Pressures",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Mohawk Industries (NYSE:MHK) has outlined a refreshed expansion and risk profile in its latest 10-K and internal SWOT analysis.</li> <li>The company is pursuing growth in Brazil and Mexico through acquisitions alongside investment in additional manufacturing capacity.</li> <li>Management is putting more emphasis on sustainability and operational efficiency while addressing legal exposures tied to PFAS and silica dust regulations.</li> </ul> <p>For investors watching the flooring and surfaces space, Mohawk Industries sits at the intersection of building products, housing activity, and renovation trends. The company‚Äôs recent disclosures describe how its global footprint and product mix relate to long term themes such as resource efficiency, regulatory scrutiny, and shifting customer preferences.</p> <p>These updates provide a clearer view of how Mohawk Industries is approaching its operations, capital spending, and risk management. When assessing NYSE:MHK, the combination of expansion in Latin America, higher manufacturing investment, and legal and environmental exposure can offer useful context for evaluating the company‚Äôs positioning across different market conditions.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-durables/nyse-mhk/mohawk-industries/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Mohawk Industries</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/MHK\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Mohawk Industries.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/consumer-durables/nyse-mhk/mohawk-industries/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:MHK Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/e802acd5-3939-495c-bb3f-8e7b17577a11/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:MHK Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_hidden_strengths\" href=\"https://www.simplywall.st/stocks/us/consumer-durables/nyse-mhk/mohawk-industries\" rel=\"noopener noreferrer\" target=\"_blank\">2 things going right for Mohawk Industries that this headline doesn't cover.</a></p> <p>For Mohawk Industries, the current plan ties together several moving pieces that matter for the business model. Capacity expansions, especially in Brazil and Mexico, point to a bigger role for emerging markets in the product mix, which can diversify away from more mature North American and European channels. At the same time, higher manufacturing investment and restructuring actions signal that management is trying to address plant efficiency gaps that have shown up in recent years. Compared with peers like Armstrong Flooring, Interface, or Shaw Industries, the focus on product development and sustainability practices such as material optimization and circularity is important in premium segments where customers pay more attention to environmental credentials.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Mohawk Industries Narrative</h3> <ul> <li>The push into emerging markets and new product lines aligns with the narrative that global diversification and premium flooring ranges can support a longer term growth profile.</li> <li>Ongoing cost pressures, restructuring, and execution risk around large capex programs could limit the margin improvement that the narrative expects from productivity initiatives.</li> <li>Legal exposures linked to PFAS and silica dust, and the potential impact of evolving regulations, are only partially reflected in many high level narratives and may warrant closer attention.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/d70wwyc4-analyst-sentiment-turns-positive-as-mohawk-industries-sees-higher-price-targets-and-buybacks\" rel=\"noopener noreferrer\" target=\"_blank\">Check out one of the top narratives in the Simply Wall St Community for Mohawk Industries</a> to help decide what it is worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Exposure to PFAS and silica dust related litigation and regulation could add to costs or constrain certain product lines.</li> <li>‚ö†Ô∏è Large manufacturing projects and restructuring plans carry execution risk if productivity gains or demand do not support the higher fixed cost base.</li> <li>üéÅ Expansion in Brazil and Mexico, along with a broader global footprint, can reduce dependence on any single housing market.</li> <li>üéÅ Product development and sustainability initiatives may help support pricing and differentiation versus flooring peers that compete mainly on cost.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, it is worth watching how quickly new capacity in Latin America ramps, and whether utilization rates justify the planned US$480 million of 2026 investment in expansion and operational improvements. Keep an eye on updates around restructuring savings, plant productivity, and any comments on pricing power in higher end laminate, LVT, and premium collections, especially versus competitors pushing promotions to win volume. Developments in PFAS and silica dust regulation, along with any new disclosures on related claims, are also important to track, as they can influence future cash needs and product decisions.</p> <p>To stay updated on how the latest news impacts the investment narrative for Mohawk Industries, visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/MHK\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Mohawk Industries</a> to follow the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 04:00:55",
            "link": "https://simplywall.st/stocks/us/consumer-durables/nyse-mhk/mohawk-industries/news/mohawk-industries-weighs-latin-america-growth-against-legal",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At NIBE Industrier (OM:NIBE B) Valuation After Germany‚Äôs Shifting Heat Pump Policies",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Germany‚Äôs 49% year-on-year jump in January heat pump subsidy applications, alongside a softer heating law that reduces renewable requirements, puts NIBE Industrier (OM:NIBE B) in a mixed position within a key market.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for NIBE Industrier.</a></p> <p>At a share price of SEK37.07, NIBE‚Äôs recent 7.57% 1 month share price return contrasts with a 7.25% decline in 1 year total shareholder return and a 65.32% drop over three years. This suggests momentum has picked up recently, while longer term holders remain under pressure.</p> <p>If Germany‚Äôs heat pump policy shift has you thinking about where future infrastructure spending could land, it may be worth checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> as a starting list of ideas.</p> <p>With NIBE trading at SEK37.07 and sitting on a 20% implied discount to one set of valuation estimates, the key question is whether recent setbacks have already reset expectations or whether the market is still pricing in ambitious future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 9.1% Undervalued</h2> <p>With NIBE Industrier‚Äôs last close at SEK37.07 against a narrative fair value of SEK40.77, the current pricing sits below what the narrative model suggests, according to Unike.</p> <blockquote> <p><em>Regulatory Support for Heat Pumps: The EU‚Äôs decarbonization plan aims for 60 million heat pumps installed by 2030, creating strong demand.</em></p> <p><em>Technological Advancements: R&amp;D in next-generation heat pumps and smart energy solutions could boost efficiency and margins.</em></p> </blockquote> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/v3mri2m5-nibe-industrier-will-ride-the-green-energy-subsidy-wave\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious how one narrative gets to that higher fair value. It leans heavily on steady expansion, firmer margins, and a future earnings multiple usually tied to premium growth stories. Want to see which specific growth and profitability assumptions sit under that headline number.</p> <p><strong>Result: Fair Value of SEK40.77 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_user_generated_narrative\" href=\"https://www.simplywall.st/narratives/v3mri2m5-nibe-industrier-will-ride-the-green-energy-subsidy-wave\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this depends on continued subsidy support and resilient end demand. Any cutbacks in incentives or a broader economic slowdown could undermine that optimistic setup.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this NIBE Industrier narrative.</a></p> <h2>Next Steps</h2> <p>Given all this, are you feeling cautious or curious about where NIBE really stands? Do not wait for someone else‚Äôs verdict. Weigh up the story yourself by checking the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> and see how the full risk reward picture lines up with your own expectations.</p> <h2>Looking for more investment ideas?</h2> <p>If this story has sharpened your thinking, do not stop here. Broaden your watchlist with a few focused idea lists built from our stock screener tools.</p> <ul> <li>Start with quality by scanning companies that pass balance sheet and fundamentals checks using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/global\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (370 results)</a> as a filter for financial resilience.</li> <li>Hunt for potential mispricing by reviewing the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">220 high quality undervalued stocks</a> and see which names currently line up with stronger fundamentals than their prices imply.</li> <li>Add some off-the-radar ideas by browsing our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/global\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 566 high quality undiscovered gems</a>, a collection that highlights businesses the market may not be fully focused on yet.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if NIBE Industrier might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 04:00:55",
            "link": "https://simplywall.st/stocks/se/capital-goods/sto-nibe-b/nibe-industrier-shares/news/a-look-at-nibe-industrier-omnibe-b-valuation-after-germanys",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Energy Recovery‚Äôs Valuation After Mixed 2025 Earnings And Recent Share Price Weakness",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Energy Recovery (ERII) shares are in focus after the company released fourth quarter and full year 2025 earnings, highlighting quarterly net income and earnings per share growth alongside slightly softer annual sales.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-erii/energy-recovery\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Energy Recovery.</a></p> <p>Despite the latest earnings update showing firmer quarterly profitability, the share price has come under pressure recently, with a 7 day share price return of 35.78% decline and a 1 year total shareholder return of 30.28% decline signaling fading momentum.</p> <p>If this pullback has you reassessing where you want exposure in the energy and infrastructure space, it could be a good moment to size up <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> as potential alternatives or complements.</p> <p>With ERII trading at a steep discount to one set of analyst expectations and an indicated intrinsic discount, the key question is whether recent weakness leaves the shares undervalued or whether the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 42.8% Undervalued</h2> <p>Energy Recovery's most followed narrative pegs fair value at $18.24 per share, well above the last close of $10.43, which frames the current pullback in a very different light.</p> <blockquote> <p><em>Momentum in energy-efficient refrigeration (CO2 PX) technology adoption, supported by rigorous OEM engagement and reliability testing, aligns with global decarbonization trends and could lead to material incremental revenue streams and improved operating leverage.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/oyb4jtgs-global-water-scarcity-and-decarbonization-will-unlock-long-term-opportunities-vvt1\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what kind of revenue path and profit margins underpin that fair value, and how long term earnings power is modeled to get there, the full narrative lays out the numbers behind that story.</p> <p><strong>Result: Fair Value of $18.24 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/oyb4jtgs-global-water-scarcity-and-decarbonization-will-unlock-long-term-opportunities-vvt1\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this story can change quickly if desalination demand shifts toward alternative technologies or if extended OEM testing slows broader adoption of PX G and CO2 refrigeration.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-erii/energy-recovery\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Energy Recovery narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of opportunity and concern feels finely balanced, it makes sense to look at the key data yourself and decide where you stand, starting with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nasdaq-erii/energy-recovery\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>Do not stop at a single stock. Widen your net with a few focused ideas from the Simply Wall St Screener so you are not second guessing later.</p> <ul> <li>Spot potential value plays early by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that currently look mispriced based on their fundamentals.</li> <li>Prioritise resilience by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">77 resilient stocks with low risk scores</a>, where companies earn stronger risk profiles and may better suit a steadier approach.</li> <li>Hunt for future leaders by reviewing a <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that the broader market may not be paying close attention to yet.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Energy Recovery might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/capital-goods/nasdaq-erii/energy-recovery/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 04:00:55",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-erii/energy-recovery/news/assessing-energy-recoverys-valuation-after-mixed-2025-earnin",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why Iovance Biotherapeutics (IOVA) Is Up 34.5% After Amtagvi-Fueled Revenue Jump And Lifileucel Fast Track",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Iovance Biotherapeutics recently reported Q4 2025 and full-year 2025 results, with revenue rising to US$86.77 million for the quarter and US$263.50 million for the year, alongside lower quarterly net loss and loss per share compared with 2024.</li> <li>At the same time, the company highlighted positive early lifileucel data in aggressive soft tissue sarcomas and secured FDA Fast Track designation for non-small cell lung cancer, underscoring how its first commercial TIL therapy Amtagvi is increasingly being leveraged across a broader pipeline.</li> <li>Next, we‚Äôll examine how the strong Amtagvi-driven revenue growth and Fast Track status for lifileucel influence Iovance‚Äôs investment narrative.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Iovance Biotherapeutics Investment Narrative Recap</h2><p>To own Iovance today, you need to believe Amtagvi can anchor a sustainable TIL franchise while lifileucel label expansions meaningfully broaden its reach. The latest results reinforce Amtagvi‚Äôs commercial traction but do not remove the key short term risk that the business is still loss making with a limited cash runway. The main near term catalyst remains further regulatory and clinical progress for lifileucel in new indications, especially non small cell lung cancer.</p> <p>The most relevant update is the FDA Fast Track designation for lifileucel in second line non small cell lung cancer, alongside positive sarcoma data and plans for a registrational soft tissue sarcoma trial. Together with Amtagvi driven revenue of US$86.77 million in Q4 2025 and a 61% full year revenue increase, this reinforces Iovance‚Äôs push to turn a single product melanoma story into a broader solid tumor platform.</p> <p>Yet in contrast to the recent momentum, investors should be aware that Iovance still has less than one year of cash runway and...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/5ucubww8-iova-advanced-melanoma-approval-and-equity-raise-will-drive-upside-potential\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Iovance Biotherapeutics (it's free!)</a></p><p>Iovance Biotherapeutics' narrative projects $744.8 million revenue and $35.6 million earnings by 2028. This requires 45.6% yearly revenue growth and a $425.5 million earnings increase from -$389.9 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/5ucubww8-iova-advanced-melanoma-approval-and-equity-raise-will-drive-upside-potential\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Iovance Biotherapeutics' forecasts yield a $8.35 fair value</a>, a 116% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IOVA 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/af2848b1-cfd3-42ac-adb3-fafd0b7d60eb/chart/quote-price\" width=\"746\"/></a><figcaption>IOVA 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest ranked analysts were assuming revenue of about US$524 million by 2028 and no profitability by then, which is far more pessimistic than the consensus view. When you compare that to today‚Äôs strong Amtagvi uptake and new Fast Track status, it shows how widely opinions can differ, and why it is worth weighing several viewpoints before you decide what this latest news could mean for your own expectations.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 10 other fair value estimates on Iovance Biotherapeutics</a> - why the stock might be worth 48% less than the current price!</p><h2>Form Your Own Verdict</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Iovance Biotherapeutics research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Iovance Biotherapeutics research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Iovance Biotherapeutics' overall financial health at a glance.</li></ul><h2>Seeking Other Investments?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 best rare earth metal stocks</a> of the very few that mine this essential strategic resource.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 03:55:52",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iova/iovance-biotherapeutics/news/why-iovance-biotherapeutics-iova-is-up-345-after-amtagvi-fue",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "ESAB Ruffian Launch And Linde Tie Up Put Valuation In Focus",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>ESAB (NYSE:ESAB) has introduced the Ruffian EMP 270G engine-driven welding generator at CONEXPO-CON/AGG 2026.</li> <li>The unit features advanced inverter technology and more than 100 customer-requested features.</li> <li>The product was developed in collaboration with Linde, with exclusive offerings tied to the trade show launch.</li> </ul> <p>ESAB, listed on the NYSE under the ticker ESAB, is a welding and cutting equipment company with a focus on industrial and construction applications. By rolling out the Ruffian EMP 270G at a major industry trade show, the company is putting a spotlight on its welding generator line and its use of inverter technology. The partnership with Linde adds another layer of interest for investors watching how ESAB works with large industrial gas and equipment players.</p> <p>For investors, this launch is mainly about how ESAB responds to customer feedback and expands its product set in engine-driven welding solutions. The combination of more than 100 customer-requested features and a high-profile debut at CONEXPO-CON/AGG 2026 provides additional information to consider when assessing ESAB's positioning in welding equipment and related services.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">ESAB</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/ESAB\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on ESAB.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:ESAB Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/105ba43f-a8da-48dd-b593-5b41ed742ebc/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:ESAB Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_full_picture\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab\" rel=\"noopener noreferrer\" target=\"_blank\">üì∞ Beyond the headline: 1 risk and 2 things going right for ESAB that every investor should see.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Investor Checklist</h2> <h3>Quick Assessment</h3> <ul> <li><strong>‚öñÔ∏è Price vs Analyst Target</strong>: ESAB trades at US$126.17 versus an analyst consensus of US$147.70, roughly 17% below the target.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: Shares are described as trading about 10.7% below an estimated fair value.</li> <li><strong>‚úÖ Recent Momentum</strong>: The 30 day return of about 7.3% points to positive short term sentiment.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold ESAB. Head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of ESAB's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The Ruffian EMP 270G launch highlights ESAB's focus on advanced inverter welding gear and customer requested features, which may influence how you view its product strength in Machinery.</li> <li>üìä Keep an eye on adoption of the new generator, any follow on product updates from the Linde partnership, and how these feed into revenue, earnings and ESAB's 30.5x P/E versus the Machinery industry average of about 28.4x.</li> <li>‚ö†Ô∏è ESAB carries a flagged risk of a high level of debt, so funding of new product lines and any future investment tied to this launch may be sensitive to balance sheet strength.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/capital-goods/nyse-esab/esab\" rel=\"noopener noreferrer\" target=\"_blank\">complete ESAB analysis</a>. Alternatively, you can check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/ESAB\" rel=\"noopener noreferrer\" target=\"_blank\">community page for ESAB</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if ESAB might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/capital-goods/nyse-esab/esab/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 03:55:52",
            "link": "https://simplywall.st/stocks/us/capital-goods/nyse-esab/esab/news/esab-ruffian-launch-and-linde-tie-up-put-valuation-in-focus",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "BrightSpring Health Services (BTSG) EPS Jump In Q4 2025 Tests Bullish Profitability Narrative",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>BrightSpring Health Services (BTSG) just closed FY 2025 with fourth quarter revenue of US$3.6b and basic EPS of US$0.24, while net income from continuing operations, excluding extra items, came in at US$49.3m. The company has seen quarterly revenue move from US$3.1b and EPS of US$0.08 in Q4 2024 to US$3.6b and EPS of US$0.24 in Q4 2025, with trailing twelve month EPS at US$0.53 and net income of US$106.3m on US$12.9b in revenue. This puts the latest report firmly in focus for anyone tracking the shift in profitability. With that backdrop, the key question for investors is how durable these margins look as the business scales through its current run rate.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for BrightSpring Health Services.</a> <p>With the headline figures on the table, the next step is to set these results against the widely held stories about BrightSpring, highlighting where the numbers back up those narratives and where they start to pull in a different direction.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/3c9bqp32-aging-population-will-transform-home-and-community-integrated-care\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about BrightSpring Health Services</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:BTSG Revenue &amp; Expenses Breakdown as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/4d909117-a897-44c6-8010-8d5f1f30d8de/chart/revenue-and-expenses-breakdown?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:BTSG Revenue &amp; Expenses Breakdown as at Feb 2026</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>TTM profit of US$106m after prior year loss</h2> <ul> <li>On a trailing twelve month basis, BrightSpring moved from a net loss of US$18.1m a year ago to net income of US$106.3m on US$12.9b of revenue.</li> <li>Consensus narrative highlights specialty pharmacy growth and efficiency projects as long term supports for earnings, and this swing into profitability lines up with that view, although:\n    <ul> <li>TTM basic EPS moved from a loss of US$0.09 to a profit of US$0.53, which fits the story of improving economics but still leaves EPS modest relative to the company‚Äôs US$41.43 share price.</li> <li>Over the past five years, earnings growth averaged a 7.4% annual decline. The recent profit contrasts with that history, so investors may treat it as early confirmation rather than a settled trend.</li> </ul> </li> </ul> <h2>Quarterly EPS climbs from US$0.05 to US$0.24</h2> <ul> <li>Within FY 2025, basic EPS moved from roughly US$0.05 in Q1 and Q2 to US$0.19 in Q3 and US$0.24 in Q4, alongside revenue rising from US$2.9b to US$3.6b over the same period.</li> <li>Bulls argue that operational improvements and specialty pharmacy momentum can keep lifting margins, and the step up in quarterly EPS speaks to that argument, but with some caveats:\n    <ul> <li>Net income, excluding extra items, increased from about US$9.7m in Q1 to US$49.3m in Q4, which strongly supports the bullish idea that the model can generate higher profit as volume scales.</li> <li>At the same time, bears point to high labor and compliance costs as ongoing pressures, and the relatively low TTM EPS of US$0.53 versus the US$41.43 share price shows that profitability is still at an early stage compared to the valuation implied by the P/E of 80.5x.</li> </ul> </li> </ul> Have the recent margin gains really changed the long term story, or are they just the first chapter in a bigger shift the bulls are hoping for, <a class=\"company-report-links\" data-vars-link-type=\"cta_bull_narrative_link\" href=\"https://simplywall.st/narratives/3c9bqp32-aging-population-will-transform-home-and-community-integrated-care\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêÇ BrightSpring Health Services Bull Case</strong></a> <h2>80.5x P/E and weak interest cover</h2> <ul> <li>The stock currently trades on a P/E of 80.5x, compared with 47x for peers and 23.7x for the wider US Healthcare sector, and interest payments are flagged as not well covered by earnings.</li> <li>Bears focus on this combination of premium multiple and balance sheet risk, and the latest numbers give them several points to work with:\n    <ul> <li>Even after reaching TTM net income of US$106.3m and EPS of US$0.53, the high P/E suggests investors are paying a large multiple of current earnings while interest coverage is described as weak, which can matter if earnings vary.</li> <li>Against that, the same dataset points to forecast earnings growth of about 29.5% a year and revenue growth around 13% a year, plus a DCF fair value of US$144.01, so the valuation debate sits between a rich current multiple and a much higher modelled DCF fair value.</li> </ul> </li> </ul> If you are weighing that rich P/E against the debt and interest coverage concerns, it can help to see how cautious analysts frame the downside, <a class=\"company-report-links\" data-vars-link-type=\"cta_bear_narrative_link\" href=\"https://simplywall.st/narratives/5lp8tja2-rising-healthcare-labor-and-regulation-will-hurt-margins-despite-automation\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêª BrightSpring Health Services Bear Case</strong></a> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/3c9bqp32-aging-population-will-transform-home-and-community-integrated-care\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for BrightSpring Health Services on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>Given the mix of confidence and concern running through this update, it makes sense to look at the details yourself and decide quickly where you stand. A helpful way to round out that view is to weigh the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a> against the latest results and narratives.</p> <h2>See What Else Is Out There</h2> <p>BrightSpring‚Äôs 80.5x P/E, modest TTM EPS of US$0.53 against a US$41.43 share price, weak interest cover, and recent loss history all signal valuation and risk concerns.</p> <p>If that mix of rich pricing and balance sheet pressure feels uncomfortable, you might want to quickly check companies in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">76 resilient stocks with low risk scores</a> that aim to pair earnings quality with lower financial strain.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if BrightSpring Health Services might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 03:55:52",
            "link": "https://simplywall.st/stocks/us/healthcare/nasdaq-btsg/brightspring-health-services/news/brightspring-health-services-btsg-eps-jump-in-q4-2025-tests",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Charles Schwab Weighs Forge Deal And AI Pressure For Future Growth",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Charles Schwab (NYSE:SCHW) is moving to acquire Forge Global Holdings to expand its private market offerings.</li> <li>The deal is intended to give Schwab clients access to a broader range of private company investments.</li> <li>At the same time, new AI tools such as Altruist's AI powered tax product are increasing technology pressure across wealth management.</li> </ul> <p>For you as an investor, this combination of events ties directly to how Schwab positions itself in wealth management and trading. The firm already sits at the center of brokerage, advisory, and custody services, and private markets are an increasingly important area for clients who want more than public stocks and bonds. The move toward private offerings is happening as digital competitors lean hard into automation and AI driven experiences.</p> <p>Schwab's Forge deal and the broader push into private markets and technology could influence how it allocates capital, prioritizes product development, and responds to new entrants. As AI driven tools spread, the question for investors is how effectively incumbents like Schwab integrate similar capabilities into their platforms and keep their large existing customer bases engaged.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Charles Schwab</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/SCHW\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Charles Schwab.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:SCHW Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/25de5f1e-74d7-4741-a39c-54d8c1f163c5/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:SCHW Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_hidden_strengths\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab\" rel=\"noopener noreferrer\" target=\"_blank\">4 things going right for Charles Schwab that this headline doesn't cover.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At US$95.20 versus a US$121.00 consensus target, the price sits about 21% below where analysts on average think it could be.</li> <li><strong>‚úÖ Simply Wall St Valuation</strong>: The shares are trading at roughly 11.6% below Simply Wall St's estimate of fair value.</li> <li><strong>‚ùå Recent Momentum</strong>: The 30 day return of about 8% decline shows recent weakness despite the deal headlines.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Charles Schwab. Head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of Charles Schwab's Fair Value</a>.</p> <h3>Key Considerations</h3> <ul> <li>üìä The Forge Global acquisition ties Schwab more closely to private markets, which could matter for how its capital markets profile and fee mix develop over time.</li> <li>üìä Keep an eye on how Schwab discusses technology spend, AI features and integration of Forge on future earnings calls and in filings.</li> <li>‚ö†Ô∏è One flagged risk is recent insider selling, which some investors may weigh against the current valuation and the new growth initiatives.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab\" rel=\"noopener noreferrer\" target=\"_blank\">complete Charles Schwab analysis</a>. Alternatively, you can visit the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/SCHW\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Charles Schwab</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 03:55:52",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-schw/charles-schwab/news/charles-schwab-weighs-forge-deal-and-ai-pressure-for-future",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Warner Bros. Discovery (WBD) One Off US$2.4b Gain Tests Bullish Profitability Narratives",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Warner Bros. Discovery (WBD) has capped FY 2025 with fourth quarter revenue of US$9.5b and a basic EPS loss of US$0.10, setting the tone for a year where profitability on a trailing basis has been supported by a sizeable one off gain. The company has seen quarterly revenue range between US$9.0b and US$9.8b across 2025, with EPS swinging from a loss of US$0.18 in Q1 to a profit of US$0.64 in Q2 before reverting to losses in Q3 and Q4. This leaves investors focusing on how much of the reported margin profile is driven by recurring operations versus that single US$2.4b boost. Overall, the latest numbers present a mixed margin picture that puts quality and durability of earnings at the centre of the earnings debate.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-wbd/warner-bros-discovery\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Warner Bros. Discovery.</a> <p>With the headline figures on the table, the next step is to set these results against the prevailing Warner Bros. Discovery narratives to see which stories about growth, profitability and risk still hold up and which ones the numbers start to challenge.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/mi9aav36-update-for-warner-bros-discovery\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about Warner Bros. Discovery</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-wbd/warner-bros-discovery/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:WBD Revenue &amp; Expenses Breakdown as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/5a050647-4c64-4012-a6f4-279b470786bf/chart/revenue-and-expenses-breakdown?date=2026-02-28\" width=\"746\"/></a><figcaption>NasdaqGS:WBD Revenue &amp; Expenses Breakdown as at Feb 2026</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Profitability helped by US$2.4b one off gain</h2> <ul> <li>On a trailing 12 month basis, Warner Bros. Discovery reports Basic EPS of US$0.29 and net income of US$727 million on US$37.3b of revenue, with management indicating that a single US$2.4b gain is a key part of that profit picture.</li> <li>Bulls argue that expanding use of franchises like Harry Potter, DC, Lord of the Rings and broader monetization of the content library can sustain earnings beyond this. However, the reliance on a large one off gain means investors have to separate recurring profitability from that US$2.4b boost.\n    <ul> <li>The bullish narrative points to multi channel revenue from theatrical, streaming, gaming, merchandise and experiences as support for earnings, while the latest year still shows three loss making quarters at the EPS level.</li> <li>Supporters of the bullish view highlight international expansion and partnerships, but the mixed quarterly net income profile, with Q1, Q3 and Q4 all reporting losses, gives a more cautious backdrop for those long term assumptions.</li> </ul> </li> </ul> <p>Bulls who think the content engine can outgrow that US$2.4b one off gain may want to see how that optimistic storyline stacks up against the full set of assumptions in the dedicated bull case for Warner Bros. Discovery. <a class=\"company-report-links\" data-vars-link-type=\"cta_bull_narrative_link\" href=\"https://simplywall.st/narratives/nz06t2qq-global-digital-trends-and-evergreen-ip-will-transform-entertainment-qsri\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêÇ Warner Bros. Discovery Bull Case</strong></a></p> <h2>High P/E and modest growth forecasts</h2> <ul> <li>The trailing P/E sits at 96.1x compared with 37x for the US Entertainment industry and 39.9x for peers, while forecasts call for earnings growth of about 9.3% per year and revenue growth of about 1.2% per year.</li> <li>Consensus narrative suggests that leveraging iconic IP and global sports plus cost discipline can support higher margins and cash flow. Yet the combination of a high P/E and modest growth expectations gives that story a relatively tight margin for error.\n    <ul> <li>Analysts expecting roughly 9.3% annual earnings growth are effectively asking the current 96.1x P/E to be supported by mid single digit style earnings growth and low single digit revenue growth.</li> <li>At the same time, revenue growth forecasts of about 1.2% per year running behind broader US market expectations sit awkwardly next to a P/E that is more than double the industry average.</li> </ul> </li> </ul> <h2>Debt costs sit against weak interest coverage</h2> <ul> <li>Analysts flag that interest payments are not well covered by earnings, which is a major financial risk even though the company has reported US$727 million of trailing 12 month net income and positive EPS on that basis.</li> <li>Bears argue that heavy debt, rising content costs and streaming competition could compress margins further, and the weak interest coverage data point gives that cautious view solid grounding.\n    <ul> <li>The fact that interest is not well covered comes alongside a mixed quarterly earnings record for FY 2025, with three out of four quarters showing net losses even before extra items.</li> <li>Critics highlight that if earnings growth comes in below the roughly 9.3% forecast, the company would have less flexibility to handle interest costs that are already described as not well covered.</li> </ul> </li> </ul> <p>Investors who focus on balance sheet resilience and the risk around interest coverage may want to see how the cautious camp lays out its arguments in the dedicated bear case for Warner Bros. Discovery. <a class=\"company-report-links\" data-vars-link-type=\"cta_bear_narrative_link\" href=\"https://simplywall.st/narratives/k1xv3y7f-margin-compression-and-debt-load-will-cripple-streaming-profitability-rwfk\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêª Warner Bros. Discovery Bear Case</strong></a></p> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/mi9aav36-update-for-warner-bros-discovery\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for Warner Bros. Discovery on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>After weighing both the bullish and cautious angles, the real question is how you see the balance between risk and reward. Move quickly, review the underlying data yourself and let our breakdown of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/media/nasdaq-wbd/warner-bros-discovery\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a> help you form a clear view.</p> <h2>See What Else Is Out There</h2> <p>WBD combines a very high 96.1x P/E, modest forecast growth and weak interest coverage, with profitability heavily influenced by a single US$2.4b gain.</p> <p>If concentration risk around debt and uneven earnings bothers you, consider checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">76 resilient stocks with low risk scores</a> to focus on companies with more resilient profiles.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Warner Bros. Discovery might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/media/nasdaq-wbd/warner-bros-discovery/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 03:55:52",
            "link": "https://simplywall.st/stocks/us/media/nasdaq-wbd/warner-bros-discovery/news/warner-bros-discovery-wbd-one-off-us24b-gain-tests-bullish-p",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Sotera Health (SHC) Is Down 7.1% After Issuing 2026 Revenue Guidance And Marking 20th Growth Year",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Sotera Health reported its fourth-quarter and full-year 2025 results on February 24, 2026, with revenue rising to US$303.44 million for the quarter and US$1.16 billion for the year, alongside higher net income and earnings per share.</li> <li>The company also issued 2026 revenue guidance of US$1.23 billion to US$1.25 billion and marked its 20th consecutive year of revenue growth, underscoring consistent demand for its sterilization and lab testing services.</li> <li>Next, we‚Äôll examine how Sotera Health‚Äôs 2026 revenue guidance and continued growth record influence its existing investment narrative and risk profile.</li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Sotera Health Investment Narrative Recap</h2><p>To own Sotera Health, you need to believe in steady demand for outsourced sterilization and lab testing, and in the company‚Äôs ability to manage heavy regulatory and legal headwinds around ethylene oxide. The latest results and 2026 guidance support the view that volume growth and pricing remain intact, but they do not materially change the key near term catalyst of execution on capacity and margin expansion, or the biggest risk around evolving EO regulations and litigation outcomes.</p> <p>The most relevant new development here is Sotera‚Äôs 2026 revenue guidance of US$1.233 billion to US$1.251 billion, which points to mid single digit growth after its 20th straight year of revenue increases. For investors focused on catalysts, this guidance helps frame how much of the expected upside still depends on sustained sterilization demand and successful capital deployment, while the backdrop of elevated regulatory driven spending and EO related legal exposure continues to shape the risk side of the story.</p> <p>Yet investors should also consider how ongoing EO litigation and regulatory costs could affect Sotera‚Äôs margins and cash generation...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/za706uvz-shc-recent-equity-offerings-and-lock-up-expiry-will-shape-market-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Sotera Health (it's free!)</a></p><p>Sotera Health's narrative projects $1.3 billion revenue and $314.2 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/za706uvz-shc-recent-equity-offerings-and-lock-up-expiry-will-shape-market-outlook\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Sotera Health's forecasts yield a $20.44 fair value</a>, a 26% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"SHC 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/81d72a34-9c37-4c95-af9a-b5d1685a5c3b/chart/quote-price\" width=\"746\"/></a><figcaption>SHC 1-Year Stock Price Chart</figcaption></figure> <p>Before this update, the most cautious analysts were assuming revenue of about US$1.4 billion and earnings of roughly US$255 million by 2029, which sits well below more optimistic views and highlights how much opinions can diverge when you weigh EO litigation risks alongside the potential benefits of Nordion‚Äôs long term Cobalt 60 positioning.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 2 other fair value estimates on Sotera Health</a> - why the stock might be worth over 2x more than the current price!</p><h2>Decide For Yourself</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Sotera Health research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Sotera Health research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Sotera Health's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 03:46:46",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-shc/sotera-health/news/sotera-health-shc-is-down-71-after-issuing-2026-revenue-guid",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Colgate-Palmolive 2030 Plan Links AI Spending To Brand And Margin Goals",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Colgate-Palmolive (NYSE:CL) has started executing its 2030 Strategic Plan, with a focus on global brand strength, product innovation grounded in scientific research, and broader demand generation.</li> <li>The company is rolling out advanced digital tools and AI across its supply chain and organization as part of this multi-year plan.</li> <li>The plan is intended to reshape how Colgate-Palmolive competes in oral care, personal care, home care, and pet nutrition categories worldwide.</li> </ul> <p>For investors watching NYSE:CL, this new plan arrives with the shares at $99.14 and multi year returns that include 43.9% over 3 years and 46.7% over 5 years. In the shorter term, the stock shows returns of 4.3% over the past week, 16.6% over the past month, and 27.6% year to date. Together, these figures help frame how the market has been pricing recent company developments.</p> <p>As Colgate-Palmolive moves through the early phases of this 2030 plan, the main questions for investors will center on how effectively it uses AI, digital tools, and scientific research to support its brands and operations. Future reporting periods will help show whether this execution approach changes the company‚Äôs competitive position and efficiency in a meaningful way.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/household/nyse-cl/colgate-palmolive/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Colgate-Palmolive</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/CL\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Colgate-Palmolive.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/household/nyse-cl/colgate-palmolive/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:CL Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/882407e9-def3-41c4-aa3f-68d09426e47f/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:CL Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/household/nyse-cl/colgate-palmolive\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 3 risks for Colgate-Palmolive. See which could impact your investment.</a></p> <p>The 2030 Strategic Plan signals that Colgate-Palmolive is trying to tighten the link between its core strengths, such as brand equity in oral and personal care, and the operational engine behind them. For you as an investor, the interesting part is less the buzzwords around AI and more whether these tools genuinely lower costs, shorten product cycles and improve on-shelf execution across both developed and emerging markets. Using data, analytics and AI-powered tools in the supply chain and marketing could help Colgate-Palmolive respond more quickly to consumer trends and retailer demands, including in e-commerce channels where competitors like Procter &amp; Gamble, Unilever and Nestl√© are active.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>How This Fits Into The Colgate-Palmolive Narrative</h3> <ul> <li>The plan to expand omnichannel reach and use digital tools is consistent with the narrative that positions emerging markets and premium oral care as long term growth drivers supported by better data and targeted marketing.</li> <li>Execution risk on restructuring and productivity programs could challenge the idea that cost savings will always be easy to reinvest while still supporting margins, especially if category growth in key markets is slower than analysts expect.</li> <li>The emphasis on AI and predictive analytics in the supply chain is an area that may not be fully captured in older narratives that focused more on product and geographic expansion than on back end efficiency gains.</li> </ul> <p>Knowing what a company is worth starts with understanding its story.\n<a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/narratives/a7tksu28-cl-future-cost-optimization-will-drive-competitive-advantage-amid-category-headwinds\" rel=\"noopener noreferrer\" target=\"_blank\">Check out one of the top narratives in the Simply Wall St Community for Colgate-Palmolive</a> to help decide what it's worth to you.</p> <h3>The Risks and Rewards Investors Should Consider</h3> <ul> <li>‚ö†Ô∏è Colgate-Palmolive is committing to multi year productivity and restructuring efforts, and if these projects disrupt operations or fall short on savings, the payoff from the 2030 plan could be limited.</li> <li>‚ö†Ô∏è The company faces category pressures and private label competition in several regions, so heavier digital and AI investment may not fully offset weaker volumes or pricing pressure in oral care and pet nutrition.</li> <li>üéÅ Colgate-Palmolive has strong global brands and exposure to emerging markets, and the 2030 plan aims to use science led product development and data driven marketing to support that position across oral care, personal care, home care and pet nutrition.</li> <li>üéÅ Analysts have identified rewards such as forecast earnings growth, a reliable dividend and a valuation that some models view as below estimated fair value, which frame how this long term plan might appeal to different investor profiles.</li> </ul> <h3>What To Watch Going Forward</h3> <p>From here, you may want to watch for concrete milestones on the 2030 plan, such as evidence of supply chain savings, new product launches backed by scientific claims and traction in e-commerce and omnichannel partnerships. Commentary around Hill‚Äôs Pet Nutrition and emerging markets like Latin America and India will also matter, given their role in previous analyst views of Colgate-Palmolive‚Äôs growth mix. Finally, pay attention to how management talks about reinvesting productivity gains into advertising and R&amp;D, and whether that shows up in brand share trends relative to peers such as Procter &amp; Gamble and Unilever.</p> <p>To ensure you're always in the loop on how the latest news impacts the investment narrative for Colgate-Palmolive, head to the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/CL\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Colgate-Palmolive</a> to never miss an update on the top community narratives.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 03:46:45",
            "link": "https://simplywall.st/stocks/us/household/nyse-cl/colgate-palmolive/news/colgate-palmolive-2030-plan-links-ai-spending-to-brand-and-m",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Disc Medicine (IRON) Valuation After Recent Share Price Swings",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Disc Medicine stock moves after recent trading swings</h2> <p>Disc Medicine (IRON) has seen sharp share price swings recently, including a negative 1 day move and gains over the past week, drawing attention to how the market is currently reacting to its hematology focused pipeline.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Disc Medicine.</a></p> <p>Those recent swings come after a 30 day share price return of a 16.74% decline and a 90 day share price return of a 28.64% decline, even as the 1 year total shareholder return of 18.58% and 3 year total shareholder return of around 7x suggest longer term momentum has been stronger.</p> <p>If these moves in Disc Medicine have you thinking about where else growth stories might emerge in healthcare, it could be worth scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 healthcare AI stocks</a> as a starting point for other ideas.</p> <p>With Disc Medicine posting a 3 year return of around 7x, trading at about a 49% discount to the average analyst price target, and showing an estimated intrinsic discount near 82%, is there genuine upside left or is the market already pricing in future growth?</p> <h2>Preferred Price to Book of 3.4x, is it justified?</h2> <p>Disc Medicine currently trades on a P/B of 3.4x, which sits between its peer group and the broader US biotech industry. That mix of signals is what many investors are trying to interpret alongside the recent share price swings.</p> <p>P/B compares the company‚Äôs market value to the book value of its net assets. This can be a useful anchor for a business like Disc Medicine that is still in the clinical stage and unprofitable. With no revenue, forecast losses over the next three years, and a reported net loss of $212.18m, the market is effectively paying a multiple of the company‚Äôs balance sheet, pipeline and intellectual property rather than current earnings.</p> <p>On one hand, the 3.4x P/B is below the peer average of 5.2x, which suggests the company is priced lower than some direct comparables. On the other hand, it is above the wider US biotech industry average of 2.7x, which indicates investors are still assigning a premium to Disc Medicine relative to the sector overall, despite the company being unprofitable and forecast to have no revenue next year. There is also a large gap between the current share price of $66.62 and both the analyst price target of $99.36 and the SWS DCF model estimate of $369.15. The market could move closer to or further from those levels as new clinical data, funding developments or insider activity, including the recent significant insider selling, come through.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a></p> <p><strong>Result: Price to Book ratio of 3.4x (ABOUT RIGHT)</strong></p> <p>However, there are still clear pressure points here, including a clinical stage pipeline with no current revenue and a recent net loss of $212.18m that could influence sentiment.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Disc Medicine narrative.</a></p> <h2>Another view: DCF points to a very different price</h2> <p>That 3.4x P/B might look roughly in line with the story so far, but our DCF model paints a very different picture. At a share price of $66.62 versus an estimated future cash flow value of $369.15, the model suggests Disc Medicine could be trading at a steep discount. Is this a genuine opportunity or a sign that the assumptions are too optimistic?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"IRON Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/2bb88255-5b25-4ce7-bb16-867fff68cc39/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>IRON Discounted Cash Flow as at Feb 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine\" rel=\"noopener noreferrer\" target=\"_blank\">check out Disc Medicine for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Mixed signals or emerging story, either way, it makes sense to look at the full picture for yourself and move quickly if you want to form a clear stance. A useful starting point is <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 3 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Disc Medicine has sharpened your focus, do not stop here. Use the Simply Wall St screener to widen your watchlist with ideas that match your style.</p> <ul> <li>Target potential mispricings by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that combine solid fundamentals with what could be more attractive entry points.</li> <li>Strengthen the foundation of your portfolio by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (39 results)</a> that put financial resilience front and center.</li> <li>Hunt for future market standouts early by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> before they land on everyone else‚Äôs radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 03:46:45",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-iron/disc-medicine/news/a-look-at-disc-medicine-iron-valuation-after-recent-share-pr",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Technology One (ASX:TNE) Is Up 5.3% After Upgrading FY26 SaaS Guidance And Insider Buying - Has The Bull Case Changed?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Technology One Limited recently increased its FY26 guidance, forecasting higher profit before tax growth and stronger annual recurring revenue, reflecting confidence in SaaS and SaaS+ demand across Australia, New Zealand and the UK.</li> <li>This guidance upgrade comes alongside ongoing board evolution and insider share purchases, underscoring management‚Äôs alignment with and commitment to the company‚Äôs SaaS-focused trajectory.</li> <li>We‚Äôll now explore how the upgraded profit and recurring revenue guidance could influence Technology One‚Äôs existing investment narrative and risk profile.</li> </ul><p>Find <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/au\" rel=\"noopener noreferrer\" target=\"_blank\">8 companies with promising cash flow potential yet trading below their fair value</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Technology One Investment Narrative Recap</h2><p>To be comfortable owning Technology One, you have to believe its shift to SaaS and now SaaS+ can keep driving dependable recurring revenue while justifying a relatively high earnings multiple. The upgraded FY26 profit and ARR guidance reinforces that storyline and likely strengthens the near term catalyst around recurring revenue growth. At the same time, it does not remove the key risk that expectations embedded in the current valuation could still prove demanding if growth slows.</p> <p>Among the recent announcements, the upgraded FY26 guidance is the most directly relevant. Lifting profit before tax growth expectations to 18% to 20% and ARR growth to 16% to 18% gives more concrete shape to the SaaS+ thesis that many investors are watching closely. Combined with continuing board refreshment and Philip Davis‚Äô initial on market share purchase, it supports a narrative of management leaning into the recurring revenue opportunity while the market reassesses shorter term share price weakness.</p> <p>But against this stronger guidance, investors should still weigh the risk that Technology One‚Äôs premium valuation could come under pressure if revenue growth in key markets were to...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/software/asx-tne/technology-one-shares/nfnd5wy8-overvaluation-will-encounter-regulatory-headwinds-and-saas-resilience-hxrs\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Technology One (it's free!)</a></p><p>Technology One‚Äôs narrative projects A$841.0 million revenue and A$224.2 million earnings by 2028. This requires 15.1% yearly revenue growth and an earnings increase of about A$91 million from A$133.0 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/software/asx-tne/technology-one-shares/nfnd5wy8-overvaluation-will-encounter-regulatory-headwinds-and-saas-resilience-hxrs\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Technology One's forecasts yield a A$34.87 fair value</a>, a 34% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"ASX:TNE 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/bb9a9557-2c31-4c59-ae97-fee24edc380a/chart/quote-price\" width=\"746\"/></a><figcaption>ASX:TNE 1-Year Stock Price Chart</figcaption></figure> <p>Some analysts were far more cautious, assuming A$857.6 million of revenue and A$219.6 million of earnings by 2028, so this guidance upgrade may eventually shift their more pessimistic view.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/au/software/asx-tne/technology-one-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 7 other fair value estimates on Technology One</a> - why the stock might be worth as much as 34% more than the current price!</p><h2>Form Your Own Verdict</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Technology One research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Technology One research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Technology One's overall financial health at a glance.</li></ul><h2>Seeking Other Investments?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/au\" rel=\"noopener noreferrer\" target=\"_blank\">7 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Technology One might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/au/software/asx-tne/technology-one-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 03:46:45",
            "link": "https://simplywall.st/stocks/au/software/asx-tne/technology-one-shares/news/technology-one-asxtne-is-up-53-after-upgrading-fy26-saas-gui",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is FulcrumAir Robotics Partnership Reshaping the Investment Case for Preformed Line Products (PLPC)?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, FulcrumAir announced a new multi-year partnership with Preformed Line Products to co-develop next-generation robotic systems for overhead power line construction, targeting improved efficiency, safety, and reliability for utilities worldwide. </li> <li>This expanded collaboration builds on earlier joint products like the LineSpider and LineFly robots, highlighting how automation could reshape how utilities build and maintain critical grid infrastructure. </li> <li>Next, we will examine how this focus on advanced robotic installation systems may influence Preformed Line Products‚Äô broader investment narrative. </li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">33 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What Is Preformed Line Products' Investment Narrative?</h2><p>For someone considering Preformed Line Products, the big picture is about believing in steady grid investment and PLP‚Äôs ability to keep turning specialized hardware and systems into resilient earnings, despite some volatility. The new FulcrumAir partnership fits neatly into this narrative: it reinforces PLP‚Äôs position in automated installation systems, but is unlikely to be a near term financial needle-mover compared with more immediate catalysts like order flow from utilities, margin trends after a softer Q3 2025, and how the business justifies its current premium P/E multiple. Where it might matter more is on the risk side: deeper integration into robotics raises execution and R&amp;D risk, but also gives PLP another way to defend its niche if competition in more traditional products intensifies.</p> But there is one operational and valuation risk in particular that investors should not ignore.\n\nPreformed Line Products' share price has been on the slide but might be dropping deeper into value territory. <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Find out whether it's a bargain at this price</a>.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PLPC 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/92e40fc7-c157-465d-983d-ab7b75e39451/chart/quote-price\" width=\"746\"/></a><figcaption>PLPC 1-Year Stock Price Chart</figcaption></figure> Two Simply Wall St Community fair value estimates span roughly US$77 to US$285, showing just how far apart private investors can be on PLP. When you set those views against the recent robotics partnership and the company‚Äôs premium earnings multiple, it underlines why understanding both growth ambitions and execution risks could matter for future performance.<p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/capital-goods/nasdaq-plpc/preformed-line-products\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 2 other fair value estimates on Preformed Line Products</a> - why the stock might be worth as much as 12% more than the current price!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Preformed Line Products research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Preformed Line Products research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Preformed Line Products' overall financial health at a glance.</li></ul><h2>Searching For A Fresh Perspective?</h2><p>Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 smaller AI-focused companies with strong growth potential</a> through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 03:41:43",
            "link": "https://simplywall.st/stocks/us/capital-goods/nasdaq-plpc/preformed-line-products/news/is-fulcrumair-robotics-partnership-reshaping-the-investment",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Ipsos (ENXTPA:IPS) Valuation After Mixed Recent Share Performance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Recent share performance and context</h2> <p>Ipsos (ENXTPA:IPS) has seen mixed share performance recently, with a 2.2% decline over the past day, a 10.9% gain over the past week, and a 3.7% decline over the past month.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/fr/media/epa-ips/ipsos-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Ipsos.</a></p> <p>At a share price of ‚Ç¨34.46, Ipsos has seen momentum fluctuate, with a 7.4% 90 day share price return set against a 25.0% decline in 1 year total shareholder return, pointing to shorter term strength after a tougher period.</p> <p>If this shift in sentiment has you looking further afield, it could be a good moment to uncover high potential names using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/global\" rel=\"noopener noreferrer\" target=\"_blank\">96 top founder-led companies</a>.</p> <p>With Ipsos trading at ‚Ç¨34.46 and both analyst targets and intrinsic estimates sitting much higher, the market seems cautious about its survey and data business. Is this a genuine opportunity, or is expected growth already priced in?</p> <h2>Most Popular Narrative: 40.2% Undervalued</h2> <p>With Ipsos last closing at ‚Ç¨34.46 against a narrative fair value of ‚Ç¨57.61, the current share price sits well below what this widely followed view suggests.</p> <blockquote> <p><em>Rapid advancements in AI and digital platforms (such as synthetic data, PersonaBots, Digital Twin Panels, and Ipsos Digital) are driving faster, more actionable insights for clients across industries, improving operational efficiency, unlocking new solutions, and contributing to structurally higher net margins and earnings thanks to a more scalable, higher margin business mix.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/dtgji4jg-leadership-transition-and-new-partnerships-will-shape-future-customer-experience-success\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what kind of revenue trajectory and margin profile could justify that gap between fair value and price? The narrative leans on compounding earnings power, disciplined cost control, and a richer mix of higher margin work. The real story sits in how these pieces are modelled together over the next few years.</p> <p><strong>Result: Fair Value of ‚Ç¨57.61 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/dtgji4jg-leadership-transition-and-new-partnerships-will-shape-future-customer-experience-success\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, that upside story could fray if public sector budgets tighten more than expected, or if recent acquisitions weigh on group margins longer than analysts anticipate.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/fr/media/epa-ips/ipsos-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Ipsos narrative.</a></p> <h2>Next Steps</h2> <p>With that mix of optimism and caution in mind, it makes sense to look at the full picture yourself and decide quickly where you stand, starting with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/fr/media/epa-ips/ipsos-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 1 important warning sign</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Ipsos has sharpened your thinking, do not stop here. Use our screeners to quickly surface fresh ideas that fit the way you like to invest.</p> <ul> <li>Target potential mispricings by scanning our market wide list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">220 high quality undervalued stocks</a> that combine solid fundamentals with attractive pricing signals.</li> <li>Prioritise resilience by checking out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/global\" rel=\"noopener noreferrer\" target=\"_blank\">325 resilient stocks with low risk scores</a> that score well on stability so you are not relying on just one name to manage volatility.</li> <li>Get ahead of the crowd by reviewing our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/global\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 566 high quality undiscovered gems</a> before they appear on everyone else's radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 03:41:43",
            "link": "https://simplywall.st/stocks/fr/media/epa-ips/ipsos-shares/news/assessing-ipsos-enxtpaips-valuation-after-mixed-recent-share",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Cohen & Steers (CNS) Valuation As Its Quarterly Dividend Is Raised To $0.67 Per Share",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Cohen &amp; Steers (CNS) has drawn investor attention after its Board of Directors approved a first quarter 2026 cash dividend of $0.67 per share, up from $0.62, payable on March 19.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Cohen &amp; Steers.</a></p> <p>Despite the higher dividend, Cohen &amp; Steers‚Äô recent trading has been mixed, with a 30-day share price return of 4.35% and a year to date share price return of 4.97%. However, the 1-year total shareholder return is a 21.13% decline, suggesting only modest momentum after a weaker year.</p> <p>If this income focused update has you thinking about where else yield and growth might intersect, it could be worth scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a> for fresh ideas beyond asset managers.</p> <p>With revenue of US$556.1m, net income of US$153.2m and a higher quarterly dividend now on the table, is Cohen &amp; Steers trading at a discount, or are markets already pricing in its future growth potential?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 7.3% Undervalued</h2> <p>With Cohen &amp; Steers last closing at $66.73 versus a narrative fair value of $72.00, the current setup hinges on how its real assets focus plays out.</p> <blockquote> <p><em>Strategic expansion into active ETFs and broader product diversification (including the launch of integrated listed/private real estate strategies) is expected to attract new investor segments and improve client retention, supporting future AUM growth and revenue stability.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/zwi3684f-active-etfs-and-global-distribution-will-drive-enduring-market-success-0fr9\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what is driving that fair value gap? The narrative leans heavily on higher earnings, richer margins and a different P/E profile than today. The full story is in the numbers.</p> <p><strong>Result: Fair Value of $72 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/zwi3684f-active-etfs-and-global-distribution-will-drive-enduring-market-success-0fr9\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, there are still watchpoints, including ongoing client outflows tied to allocation shifts, as well as rising costs from global expansion and new product launches that could pressure margins.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Cohen &amp; Steers narrative.</a></p> <h2>Another Take On Valuation</h2> <p>That $72 fair value from the narrative sits alongside a different signal from earnings based pricing. Cohen &amp; Steers trades on a P/E of 22.2x, which is below the US Capital Markets average of 23.4x but above our fair ratio of 15.3x. So is this a quality premium or just valuation risk building up?</p> <p>To see how those P/E gaps stack up against history and peers in a bit more detail, <a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price ‚Äî find out in our valuation breakdown.</a> can help you pressure test whether the current price feels comfortable for your own risk tolerance.</p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/diversified-financials/nyse-cns/cohen-steers/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:CNS P/E Ratio as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/16375567-5596-4006-a545-c3cc054a6e10/chart/pe-multiple-vs-industry?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:CNS P/E Ratio as at Feb 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>If this mix of income appeal and valuation questions leaves you on the fence, now is a good time to review the full picture yourself, including <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Cohen &amp; Steers is only one piece of your watchlist, now is the moment to line up a few more ideas before the next move catches you off guard.</p> <ul> <li>Spot income opportunities by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that may appeal if you want yields with a focus on resilience.</li> <li>Hunt for potential value by checking <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> where solid fundamentals meet prices that some investors may see as appealing.</li> <li>Strengthen your watchlist with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">77 resilient stocks with low risk scores</a> that aim to balance return potential with lower overall risk scores.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 03:41:43",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-cns/cohen-steers/news/a-look-at-cohen-steers-cns-valuation-as-its-quarterly-divide",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Cloudflare Deepens Security Role With Post Quantum SASE And Mastercard Pact",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Cloudflare launched what it calls the first complete Secure Access Service Edge platform with post-quantum encryption across its services.</li> <li>The company also announced a cybersecurity partnership with Mastercard aimed at protecting critical infrastructure and small businesses with real time, risk driven defenses.</li> </ul> <p>Cloudflare, trading on the NYSE under ticker NYSE:NET, sits at the intersection of networking and security. This move pushes more of its product stack into the security spotlight. The stock last closed at $172.19, with a 1 year return of 18.5% and a 3 year return of 179.6%. These figures put the announcements into focus for investors following the company's evolution. The 5 year return of 156.9% offers a longer lens on how the market has treated Cloudflare's role in internet infrastructure.</p> <p>In the near term, investors watching NYSE:NET are likely to focus on how post-quantum encryption and the Mastercard partnership translate into product adoption and customer stickiness. As quantum computing risk and attacks on payment systems and small businesses receive more attention, Cloudflare's positioning around end to end cryptography and real time threat screening may become a more central part of how the company is evaluated.</p> <p>Stay updated on the most important news stories for <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Cloudflare</a> by adding it to your <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a>. Alternatively, explore our <a class=\"company-report-links\" data-vars-link-type=\"news_stay_updated_cta\" href=\"https://simplywall.st/stock/NYSE/NET\" rel=\"noopener noreferrer\" target=\"_blank\">Community</a> to discover new perspectives on Cloudflare.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare/future\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:NET Earnings &amp; Revenue Growth as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/46496791-fd68-4f67-818a-7ac8ce86e3d7/chart/earnings-and-revenue-growth?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:NET Earnings &amp; Revenue Growth as at Feb 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_news_risk_alert\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare\" rel=\"noopener noreferrer\" target=\"_blank\">We've flagged 1 risk for Cloudflare. See which could impact your investment.</a></p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Quick Assessment</h3> <ul> <li><strong>‚úÖ Price vs Analyst Target</strong>: At US$172.19 versus a consensus target of about US$231.30, the price sits roughly 34% below where analysts, on average, think it could be.</li> <li><strong>‚ùå Simply Wall St Valuation</strong>: The shares are described as trading 70.8% above an estimated fair value, which flags a rich valuation on that model.</li> <li><strong>‚ùå Recent Momentum</strong>: A 30 day return of about 6.9% decline suggests recent pressure despite the product and partnership news.</li> </ul> <p>There is only one way to know the right time to buy, sell or hold Cloudflare: head to Simply Wall St's\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">company report for the latest analysis of Cloudflare's Fair Value.</a></p> <h3>Key Considerations</h3> <ul> <li>üìä The SASE launch with post quantum encryption, plus the Mastercard tie up, pushes Cloudflare deeper into security and payments adjacent workloads, which some investors may see as broadening its role in internet infrastructure.</li> <li>üìä Watch how large customers adopt the new SASE offering, any traction in deals linked to Mastercard, and whether revenue and earnings forecasts are updated in response.</li> <li>‚ö†Ô∏è With one flagged risk around recent insider selling and shares sitting well above an estimated fair value, execution on these products will be important if sentiment cools.</li> </ul> <h3>Dig Deeper</h3> <p>For the full picture, including more risks and rewards, check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/software/nyse-net/cloudflare\" rel=\"noopener noreferrer\" target=\"_blank\">complete Cloudflare analysis</a>. Alternatively, you can check out the\n<a class=\"company-report-links\" href=\"https://www.simplywall.st/stock/NYSE/NET\" rel=\"noopener noreferrer\" target=\"_blank\">community page for Cloudflare</a> to see how other investors believe this latest news will impact the company's narrative.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>‚Ä¢ Dividend Powerhouses (3%+ Yield)<br/>‚Ä¢ Undervalued Small Caps with Insider Buying<br/>‚Ä¢ High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 03:41:43",
            "link": "https://simplywall.st/stocks/us/software/nyse-net/cloudflare/news/cloudflare-deepens-security-role-with-post-quantum-sase-and",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Daktronics (DAKT) Valuation After Strong Recent Share Price Momentum",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Daktronics (DAKT) has drawn fresh attention after recent trading, with the share price at US$25.78 and returns over the past month and past 3 months noticeably different from its moves in the last week.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-dakt/daktronics\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Daktronics.</a></p> <p>That recent 7 day share price return of 7.03% and 1 day move of 3.08% sit against a 30 day share price return of 17.56% and year to date share price return of 29.94%. The 1 year total shareholder return of 68.94% suggests momentum has been strong over a longer stretch even after the latest pullback.</p> <p>If Daktronics has you thinking about where growth and risk might show up next in tech hardware and infrastructure, it could be worth scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_power_grid\" href=\"https://simplywall.st/discover/investing-ideas/473750/power-grid-technology-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">23 power grid technology and infrastructure stocks</a> as a fresh source of ideas.</p> <p>With Daktronics trading at US$25.78 against a US$30.00 analyst price target and a value score of 2, you might ask: is the stock still undervalued or is the market already pricing in future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 14.1% Undervalued</h2> <p>At $25.78 against a fair value estimate of $30.00, the most followed narrative sees Daktronics trading below its assessed worth while still applying a disciplined discount rate of 8.39%.</p> <blockquote> <p><em>The accelerating adoption of digital displays in sectors like retail, sports, transportation, and public spaces is expanding Daktronics' addressable market, as seen in strong order growth, record high school recreation bookings, and increasing live events projects, creating a substantial revenue tailwind and supporting long-term topline growth.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/9vf6f0if-digital-displays-and-smart-cities-will-open-new-markets-nin6\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what kind of revenue run rate, margin profile, and future earnings multiple have to line up for that $30.00 fair value to hold? The narrative leans on meaningful earnings step ups, a firmer profit margin base, and a valuation multiple that still sits below many peers, but the exact mix of those inputs only becomes clear when you see the full set of assumptions.</p> <p><strong>Result: Fair Value of $30.00 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/9vf6f0if-digital-displays-and-smart-cities-will-open-new-markets-nin6\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this depends on cyclical end markets and tariff exposure not having a greater impact than expected, and on large project timing not slipping enough to unsettle that narrative.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-dakt/daktronics\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Daktronics narrative.</a></p> <h2>Another Angle On Value</h2> <p>Our DCF model reaches a very different conclusion to the $30.00 fair value narrative, with an estimate of $13.77 per share. On that view, Daktronics at $25.78 screens as expensive rather than undervalued. This raises a simple question for you: which story feels more realistic?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-dakt/daktronics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/tech/nasdaq-dakt/daktronics/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"DAKT Discounted Cash Flow as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a943fbe1-0950-48d7-a53d-4fe77fcdeb02/chart/dcf?date=2026-02-28\" width=\"746\"/></a><figcaption>DAKT Discounted Cash Flow as at Feb 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-dakt/daktronics\" rel=\"noopener noreferrer\" target=\"_blank\">check out Daktronics for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>If this mix of confidence and concern around Daktronics leaves you on the fence, act while the data is fresh and shape your own view with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/tech/nasdaq-dakt/daktronics\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Daktronics has sharpened your thinking, do not stop here. Use the Simply Wall St screener to hunt for fresh opportunities that fit your style.</p> <ul> <li>Target potential mispricings by scanning <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that pair solid fundamentals with prices that may not fully reflect their underlying business strength.</li> <li>Strengthen your income stream by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that focus on companies offering higher yields with an emphasis on resilience.</li> <li>Protect your downside by checking <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">77 resilient stocks with low risk scores</a> that prioritise balance sheet quality and lower overall risk profiles.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 03:36:36",
            "link": "https://simplywall.st/stocks/us/tech/nasdaq-dakt/daktronics/news/assessing-daktronics-dakt-valuation-after-strong-recent-shar",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Primo Brands (PRMB) Q4 Loss Tests Bullish Margin Expansion Narrative",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Primo Brands (PRMB) closed FY 2025 with Q4 revenue of US$1.6b and basic EPS of a US$0.07 loss, capping off a trailing twelve month period where revenue reached US$6.7b and EPS came in at US$0.22. Over recent quarters, the company has seen revenue range from US$1.4b in Q4 FY 2024 to US$1.8b in Q3 FY 2025, while quarterly EPS moved between a US$0.49 loss and US$0.24. This set the scene for a year that turned profitable on a trailing basis despite a softer fourth quarter. For investors, the mix of full year profitability and a weaker finish puts the spotlight squarely on how much of that EPS reflects improving margins versus quarter to quarter volatility.</p> <a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis_earnings\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nyse-prmb/primo-brands\" rel=\"noopener noreferrer\" target=\"_blank\">See our full analysis for Primo Brands.</a> <p>With the headline numbers on the table, the next step is to weigh them against the key market narratives that have built up around Primo, to see which stories the latest margins support and which ones start to look out of date.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_range_narrative\" href=\"https://www.simplywall.st/narratives/bwzp1i4m-update-for-primo-brands\" rel=\"noopener noreferrer\" target=\"_blank\">See what the community is saying about Primo Brands</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nyse-prmb/primo-brands/past\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:PRMB Earnings &amp; Revenue History as at Feb 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3498537d-e35f-4499-862a-ad419eca9638/chart/earnings-and-revenue-history?date=2026-02-28\" width=\"746\"/></a><figcaption>NYSE:PRMB Earnings &amp; Revenue History as at Feb 2026</figcaption></figure> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>TTM profit of US$80.4m built on much stronger recent quarters</h2> <ul> <li>On a trailing 12 month basis, Primo earned US$80.4m of net income excluding extra items, compared with individual quarterly results that swung from a US$153.9m loss in Q4 FY 2024 to profits of US$34.7m, US$30.5m and US$40.5m in the first three quarters of FY 2025.</li> <li>Bulls point to this move into profitability as backing their view of improving fundamentals, yet the path has not been smooth:\n    <ul> <li>Consensus narrative highlights that analysts see earnings growing meaningfully with forecast annual growth around 61.3%, while revenue is only forecast to grow about 2.1% per year, so a lot rests on margins continuing to support that US$80.4m TTM profit level.</li> <li>At the same time, the risk summary flags a US$326.0m one off loss in the last 12 months, so some of the big swing in reported profit and loss is tied to unusual items rather than a simple, steady earnings path.</li> </ul> </li> </ul> <h2>Q4 loss of US$25.3m contrasts with earlier FY 2025 profits</h2> <ul> <li>Q4 FY 2025 showed a net income loss of US$25.3m excluding extra items, following three quarters of profits in FY 2025 of US$34.7m, US$30.5m and US$40.5m, so the full year profitability came alongside a weaker finish.</li> <li>Bears focus on this softer end to the year when they question the earnings path:\n    <ul> <li>The bearish narrative notes that the home and office delivery channel has seen low single digit net sales declines and that extra routes, labor and customer support have been needed, and the Q4 loss lines up with that concern that integration and service issues can weigh on profitability.</li> <li>Critics also point to weak interest coverage in the risk summary, which, together with a quarterly loss despite earlier profits, supports their view that the earnings profile can be sensitive to higher costs and financial obligations.</li> </ul> </li> </ul> If you are wondering how much of this profit swing really fits the optimistic story, bulls argue that premium brands and merger synergies could keep lifting margins over time, while the latest numbers show both progress and bumps along the way. <a class=\"company-report-links\" data-vars-link-type=\"cta_bull_narrative_link\" href=\"https://simplywall.st/narratives/rduist81-update-for-primo-brands\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêÇ Primo Brands Bull Case</strong></a> <h2>High P/E and DCF gap leave mixed valuation signals</h2> <ul> <li>With the share price at US$22.68, analysts cite an overall price target of US$26.83 and a DCF fair value of US$63.35, yet the stock also trades on a P/E of 102.7x compared with a global beverage industry average of 17.6x and a peer average of 26.3x.</li> <li>Bears argue that this combination of a high P/E and financial risks is hard to ignore:\n    <ul> <li>The risk summary notes that interest payments are not well covered by earnings and that dividend payments at a 2.12% yield are not well covered, which adds pressure when the valuation multiple is already far above industry levels.</li> <li>At the same time, the share price sitting below the US$63.35 DCF fair value and under the US$26.83 analyst target means valuation signals pull in opposite directions, so skeptics question whether the high multiple is justified until earnings and balance sheet metrics improve further.</li> </ul> </li> </ul> For a cautious read on these stretched valuation metrics, some investors look at how bears frame the risks around leverage, interest coverage and payout sustainability before deciding how comfortable they are with a 102.7x P/E. <a class=\"company-report-links\" data-vars-link-type=\"cta_bear_narrative_link\" href=\"https://simplywall.st/narratives/bwzp1i4m-update-for-primo-brands\" rel=\"noopener noreferrer\" target=\"_blank\"><strong>üêª Primo Brands Bear Case</strong></a> <h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://www.simplywall.st/narratives/bwzp1i4m-update-for-primo-brands\" rel=\"noopener noreferrer\" target=\"_blank\">community narratives</a> for Primo Brands on Simply Wall St. Add the company to your <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"conclusion_cta_when_narratives_exist\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> so you'll be alerted when the story evolves.</p> <p>Mixed signals on growth, profitability and valuation can feel messy, so it is worth moving quickly, checking the numbers yourself and weighing the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/food-beverage-tobacco/nyse-prmb/primo-brands\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 3 important warning signs</a> before you decide what they add up to.</p> <h2>See What Else Is Out There</h2> <p>Primo's mix of a Q4 loss, weak interest and dividend coverage, and a 102.7x P/E against peers highlights meaningful pressure on both earnings quality and risk.</p> <p>If that combination of a stretched multiple and fragile coverage ratios feels uncomfortable, take a look at <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">77 resilient stocks with low risk scores</a> to quickly focus on companies where balance sheets and risk scores may offer more resilience.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>‚Ä¢ Connect an unlimited number of Portfolios and see your total in one currency<br/>‚Ä¢ Be alerted to new Warning Signs or Risks via email or mobile<br/>‚Ä¢ Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 03:36:36",
            "link": "https://simplywall.st/stocks/us/food-beverage-tobacco/nyse-prmb/primo-brands/news/primo-brands-prmb-q4-loss-tests-bullish-margin-expansion-nar",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}